富祥药业
(300497)
| 流通市值：46.20亿 | | | 总市值：56.45亿 |
| 流通股本：4.41亿 | | | 总股本：5.39亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 514,674,060.06 | 233,698,855.18 | 1,177,846,602.65 | 976,875,468.35 |
| 营业收入 | 514,674,060.06 | 233,698,855.18 | 1,177,846,602.65 | 976,875,468.35 |
| 二、营业总成本 | 551,334,176.2 | 253,587,100.76 | 1,337,440,791.2 | 1,077,531,750.26 |
| 营业成本 | 429,898,172.31 | 198,347,430.62 | 1,064,004,196.21 | 880,028,133.92 |
| 税金及附加 | 8,275,131.11 | 3,993,791.23 | 16,655,615.75 | 12,627,267.45 |
| 销售费用 | 6,172,311.29 | 2,232,179.63 | 16,785,580.5 | 12,646,119.93 |
| 管理费用 | 59,641,982.06 | 25,621,508.77 | 138,804,275.26 | 94,661,815.6 |
| 研发费用 | 29,920,250.93 | 14,056,871.48 | 74,659,178.56 | 54,877,753.79 |
| 财务费用 | 17,426,328.5 | 9,335,319.03 | 26,531,944.92 | 22,690,659.57 |
| 其中:利息费用 | 20,220,585.12 | 10,417,538.42 | 40,578,533.6 | 30,589,566 |
| 其中:利息收入 | 3,175,562.31 | 1,413,009.19 | 6,676,480.95 | 5,474,334.4 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -241,789.26 | - |
| 加:投资收益 | -1,112,325.63 | 50,439.06 | -13,743,691.53 | -1,081,409.46 |
| 资产处置收益 | 13,578.77 | - | -103,508.54 | -104,670.72 |
| 资产减值损失(新) | 557,832.3 | -7,122,360.18 | -156,720,544.37 | -764,171.65 |
| 信用减值损失(新) | 3,408,890.92 | 5,057,103.41 | -685,717 | -1,241,930.39 |
| 其他收益 | 30,831,823.21 | 29,050,274.3 | 44,017,754.15 | 41,017,587.27 |
| 四、营业利润 | -2,960,316.57 | 7,147,211.01 | -287,071,685.1 | -62,830,876.86 |
| 加:营业外收入 | 1,130,733.1 | 706,424.26 | 820,067.02 | 383,574.65 |
| 减:营业外支出 | 987,024.6 | 141,329.44 | 2,312,203.96 | 723,058.89 |
| 五、利润总额 | -2,816,608.07 | 7,712,305.83 | -288,563,822.04 | -63,170,361.1 |
| 减:所得税费用 | 7,176,325.4 | 7,103,011.36 | -8,112,693.18 | 6,037,125.6 |
| 六、净利润 | -9,992,933.47 | 609,294.47 | -280,451,128.86 | -69,207,486.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -9,992,933.47 | 609,294.47 | -280,451,128.86 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -6,911,150.65 | 2,238,811.99 | -272,100,550.53 | -62,074,959.23 |
| 少数股东损益 | -3,081,782.82 | -1,629,517.52 | -8,350,578.33 | -7,132,527.47 |
| 扣除非经常损益后的净利润 | -32,179,814.27 | -22,599,640.05 | -304,529,910.9 | -94,188,962.65 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | 0 | -0.51 | -0.12 |
| (二)稀释每股收益 | -0.01 | 0 | -0.51 | -0.12 |
| 八、其他综合收益 | - | - | 1,011,546.71 | - |
| 归属于母公司股东的其他综合收益 | - | - | 1,011,546.71 | - |
| 九、综合收益总额 | -9,992,933.47 | 609,294.47 | -279,439,582.15 | -69,207,486.7 |
| 归属于母公司股东的综合收益总额 | -6,911,150.65 | 2,238,811.99 | -271,089,003.82 | -62,074,959.23 |
| 归属于少数股东的综合收益总额 | -3,081,782.82 | -1,629,517.52 | -8,350,578.33 | -7,132,527.47 |
| 公告日期 | 2025-08-27 | 2025-04-26 | 2025-04-26 | 2024-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |